JAMA urges journals to toughen data review

My lede:

Medical journal editors should require independent analysis of industry-sponsored trial data by an academic statistician before publishing results, according to an editorial published in the March 24/31 Journal of the American Medical Association.

The call comes in response to internal GlaxoSmithKline documents revealed as part of a February Senate Finance Committee report investigating the company’s handling of data related to its diabetes drug Avandia (rosiglitazone).

The whole shebang.